All content on this website is provided for educational and research purposes only. It does not constitute medical advice or treatment. This article discusses biological mechanisms also observed in laboratory and preclinical research models, so no clinical efficacy or safety for human use is implied. The substances discussed, which are not registered medicines, are not intended for use in humans or animals.

GHRP-2 peptide

GHRP-2 peptide is a synthetic peptide belonging to a class of compounds known as growth hormone releasing peptides (GHRPs). These peptides are studied for their ability to stimulate the release of growth hormone (GH) from the pituitary gland by activating signaling pathways related to the hormone ghrelin. GHRP-2 was originally developed as part of pharmaceutical research investigating compounds capable of stimulating natural growth hormone secretion.

Although GHRP-2 peptide has been widely studied in endocrine research, it is generally considered an experimental compound and has not been approved as a pharmaceutical medication in most regulatory jurisdictions.

How GHRP-2 peptide works

GHRP-2 acts primarily by activating the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a) in the pituitary gland and hypothalamus. Activation of this receptor may lead to:

  • stimulation of growth hormone secretion from the pituitary gland

  • increases in circulating insulin-like growth factor-1 (IGF-1) through the GH axis

  • modulation of certain neuroendocrine pathways related to metabolism and appetite

Compared with some earlier compounds in this class, GHRP-2 has been shown in experimental studies to produce relatively strong stimulation of growth hormone release.

Because of these properties, it has been investigated in research related to endocrine function, metabolism, and growth hormone physiology.

Clinical trials and evidence

GHRP-2 peptide has been evaluated in several clinical and experimental studies examining its effects on growth hormone secretion. Research has explored its potential use in areas such as:

  • diagnostic testing of growth hormone secretion

  • studies involving growth hormone deficiency

  • experimental investigations of neuroendocrine regulation

Some studies have confirmed that GHRP-2 can stimulate measurable increases in circulating growth hormone levels.

However, despite these findings, the peptide did not progress to widespread clinical use, and most available data come from early-stage clinical studies and laboratory research.

Possible side effects of GHRP-2 peptide:

Because GHRP-2 influences hormonal pathways related to growth hormone signaling, potential side effects may include:

  • headache

  • flushing

  • fatigue

  • temporary increases in appetite

  • injection site reactions

As with other investigational peptides affecting endocrine pathways, the long-term safety profile has not been fully established.

GHRP-2 is considered an experimental peptide used primarily in research settings and is not approved as a prescription medication by major regulatory authorities. Scientific research involving such compounds should be conducted with appropriate safety precautions and in accordance with applicable laws and regulations in the relevant country.

The purpose of this website is to provide clear, evidence-based information about biologically active compounds often discussed in research, metabolic health, and biohacking communities. The information presented here is educational and should not be considered medical advice.

GHRP-2
Action: Growth hormone stimulation | Category: ghrelin receptor agonist
Experimental dosage: 100–200 mcg | Frequency: 2–3× a day | Timing: fasted | Cycle on: 8 weeks — Route: subcutaneous (SC). Stop rules: hold and seek medical advice if moderate/severe adverse effects occur (e.g., escalating nausea/vomiting, dizziness, palpitations, significant blood pressure changes, severe injection‑site reactions, allergic symptoms) or if there is no clear ‘return‑to‑baseline’ window between doses. | Cycle off: 4 weeks
Effectiveness: ■■■▢▢ | Safety: ■■▢▢▢

Related peptides

Peptides from the same functional group:AOD9604, CJC-1295 NO DAC, CJC-1295 with DAC, GHRP-6, Hexarelin, Ipamorelin

Our peptides database

5-Amino-1MQ | AICAR peptide | AOD9604 peptide | Arg-BPC-157 peptide | BPC-157 peptide | CagriSema | Cerebrolysin peptide | CJC-1295 NO DAC peptide | CJC-1295 with DAC peptide | Cortagen peptide | Dihexa peptide | DSIP peptide (Delta Sleep-Inducing Peptide) | Dulaglutide peptide | Epithalon peptide | Exenatide peptide | Follistatin 315 peptide | Follistatin 344 peptide | FOXO4-DRI peptide | GHK-Cu peptide | GHRP-2 peptide | GHRP-6 peptide | Hexarelin peptide | HGH Fragment 176-191 | Humanin peptide | IGF-1 LR3 peptide | Ipamorelin CJC-1295 NO DAC | Ipamorelin peptide | Kisspeptin peptide | KPV peptide | L-Carnitine | Liraglutide peptide | Livagen peptide | LL-37 peptide | Matrixyl peptide | Mazdutide peptide | Melanotan II peptide | Melanotan peptide | MGF peptide (Mechano Growth Factor peptide) | MOD GRF 1-29 | MOTS-C peptide | NAD+ coenzime (Nicotinamide Adenine Dinucleotide) | Oxytocin peptide | P21 peptide | PEG-MGF peptide | Pinealon peptide | PT-141 peptide (Bremelanotide) | PTD-DBM peptide | Retatrutide | Selank peptide | Semaglutide | Semax peptide | Sermorelin peptide | SHLP-2 peptide | SHLP-6 peptide | Somatropin peptide | SS-31 peptide (Elamipretide) | TB-500 peptide | Tesamorelin peptide | Thymosin Alpha 1 peptide | Thymosin beta 4 peptide | Thymosin β10 peptide | Thymulin peptide | Tirzepatide | Vilon peptide
Tagged